Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameYestar Health
Stock Code02393
Company Full NameTo be extracted
IndustryIndustrial Goods
Principal Activities中國領先的彩色相紙供應商之一,亦是多種影像產品的供應商,通過分切及縱切將彩色相紙大軸剪裁成訂製尺寸,加工即用型彩色相紙、多種影像打印膠片及醫學影像膠片;並為富士膠片彩色相紙及彩色膠片在中國最大的授權經銷商及加工商。
Listing Date2013-10-11
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海閔行區莘建東路58號2棟805室
Business Address (Hong Kong)香港灣仔告士打道109-111號東惠商業大廈2403室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.yestarcorp.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.38 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2013-09-27 to 2013-10-03
Global Offering Shares112,500,000 shares
HK Public Offer Shares (Initial)11,250,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)101,250,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO450,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 155,250,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 167.4M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +5704%

Valuation & Financials

Market Cap (at Offer Price)HK$ 598,500,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币58.0百万元
Period-End Cash Balance人民币160.4百万元
Listing Expenses~HK$ 47,200,000
Listing Expenses / Funds Raised~30.4%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2010201120122013-05
Revenue 523,177977,098955,818414,024
Cost of sales -437,873-813,679-788,508-340,354
Gross profit 85,304163,419167,31073,670
Other income and gains, net 8,18410,8348,4682,444
Selling and distribution expenses -38,464-55,777-49,638-21,266
Administrative expenses -24,694-41,465-41,101-21,866
Operating profit 29,79472,86584,44832,656
Net finance costs -2,603-3,562-2,875-1,739
Profit before tax 27,19169,30381,57330,917
Income tax expense -5,515-21,008-23,540-10,797
Profit for the year 21,67648,29558,03320,120
Profit attributable to owners 19,29747,31256,51720,281
Balance Sheet
Item 2010201120122013-05
Cash and cash equivalents 68,537142,039160,393135,204
Trade and bills receivables 11,82636,941100,754117,360
Inventories 143,093132,827177,768228,707
Total current assets 277,257401,435467,673531,235
Total assets 339,296475,861587,201664,587
Total current liabilities 187,039289,145407,937462,992
Total liabilities 206,004294,274438,098495,364
Total equity 133,292181,587149,103169,223
Equity attributable to owners 111,123158,435140,153160,434
Interest-bearing borrowings 37,00046,60045,00065,000
Cash Flow Statement
Item 2010201120122013-05
Net cash from operating activities 53,842100,07744,638-21,354
Net cash from investing activities -23,747-32,613-21,816-24,882
Net cash from financing activities -2,4356,038-4,46821,047
Net increase in cash 27,66073,50218,354-25,189
Depreciation of PP&E 8,9329,3829,3164,852
Amortisation of intangible assets 464558475214
Purchase of PP&E -17,908-6,893-51,883-17,717
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.58
First Day OpenHK$ 1.61
First Day Change-1.04%
First Day Volume35010000.0
First Day Turnover55221000.0
Use of Proceeds
1、約35%所得款項凈額或3770萬港幣將用于購置設備及用作成立全印館網絡的開辦費用; 2、約30%所得款項凈額或3230萬港幣將用作收購一間用于全國銷售網絡、生產能力及在中國從事醫用X射線設備業務所需牌照的醫療設備公司的全部或大部分權益; 3、約15%所得款項凈額或1620萬港幣將用作擴充本公司的加工能力及興建加工設施; 4、約10%所得款項凈額或1080萬港幣將用研發活動; 5、約10%所得款項凈額或1080萬港幣將用公司一般營運資金及其他用途。

Underwriting Syndicate

Sole Sponsor (1)
海通国际资本有限公司 CE ADQ859
Overall Coordinators (1)
海通国际证券有限公司 CE AAF806
Joint Bookrunners (2)
海通国际证券有限公司 CE AAF806 中国银河国际证券(香港)有限公司 CE AXM459
Joint Lead Managers (2)
海通国际证券有限公司 CE AAF806 中国银河国际证券(香港)有限公司 CE AXM459

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman何震發—
Company Secretary高卓安—
No director data available.

Major Shareholders

Major Shareholders & HoldingsJeane Hartono(37.61%)、何震發(14.75%)、Rico Hartono(14.75%)、Chen Chen Irene Hartono(6.64%);控股股東合共約73.73%
About this page

This page shows Yestar Health (02393) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect